⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochlorthiazide SCHEMBL450348 | 0.96 | — | — | |
| Hydrochlorthiazide SCHEMBL6291 | 0.96 | — | — | |
| Hydrochlorthiazide SCHEMBL9336266 | 0.96 | — | — | |
| Hydrochlorthiazide SCHEMBL3110285 | 0.96 | — | — | |
| Hydrochlorthiazide SCHEMBL25294605 | 0.93 | — | — | |
| Hydrochlorthiazide SCHEMBL250706 | 0.93 | — | — | |
| Hydrochlorthiazide SCHEMBL271146 | 0.93 | — | — | |
| Hydrochlorthiazide SCHEMBL2230375 | 0.93 | — | — | |
| Hydrochlorthiazide SCHEMBL291944 | 0.93 | — | — | |
| Hydrochlorthiazide SCHEMBL3577013 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103608346-B | As the 7-naphthyridine derivatives of hypoxia inducible factor (HIF) hydroxylase inhibitors | 菲布罗根有限公司 | 2016-06-15 | — | — | CN | disclosed |
| US-9174949-B2 | Hedgehog inhibitors | SELEXAGEN THERAPEUTICS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| CN-103608346-A | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN INC | 2014-02-26 | — | — | CN | disclosed |
| US-20130012513-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| CN-102802419-A | HEDGEHOG inhibitors | SELEXAGEN THERAPEUTICS INC | 2012-11-28 | — | — | CN | disclosed |
| EP-2521451-A1 | HEDGEHOG INHIBITORS | Selexagen Therapeutics, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2011085128-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085261-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-7718612-B2 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008019303-A2 | PYRIDAZINONYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20040180815-A1 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | NAKAJIMA SUANNE (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |